Leads the global Clinical Development organization encompassing clinical pharmacology services, full service clinical trial and product development capabilities, scientific and therapeutic expertise, FSP and hybrid models, and digital and mobile health solutions
Responsible for ensuring a product development mindset throughout the organization; Focused on maximizing the return on investments for customers, providing an exceptional customer experience and achieving growth targets; Implements innovative solutions through integrated Syneos Health commercial capabilities, patient and healthcare professional insights and digital engagement
25+ years of clinical development and commercialization experience; strong track record of transforming business units and companies, setting strategy and spearheading high-value solutions across the product development lifecycle
Brings extensive global product development experience to Syneos Health from prior roles, including serving as President & Global Head at LabCorp (Covance) Clinical Development & Commercialization Services and Executive Vice President & Global Head of Clinical Development at PRA Health Sciences encompassing work across phase I-IV, FSP, clinical pharmacology/phase I units, real-world outcomes/post marketing, consulting, commercial services and global service delivery hubs in China and India
Bachelor of Science, North Carolina State University; Member, College of Sciences Foundation Board of Directors, North Carolina State University
What is Michael Lee Brooks' net worth?
The estimated net worth of Michael Lee Brooks is at least $1.79 million as of July 28th, 2022. Mr. Brooks owns 47,552 shares of Syneos Health stock worth more than $1,794,137 as of February 6th. This net worth evaluation does not reflect any other assets that Mr. Brooks may own. Learn More about Michael Lee Brooks' net worth.
How do I contact Michael Lee Brooks?
Has Michael Lee Brooks been buying or selling shares of Syneos Health?
Michael Lee Brooks has not been actively trading shares of Syneos Health in the last ninety days. Most recently, Michael Lee Brooks sold 1,002 shares of the business's stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $78.00, for a transaction totalling $78,156.00. Following the completion of the sale, the chief operating officer now directly owns 47,552 shares of the company's stock, valued at $3,709,056. Learn More on Michael Lee Brooks' trading history.
Who are Syneos Health's active insiders?
Are insiders buying or selling shares of Syneos Health?
During the last twelve months, insiders at the sold shares 8 times. They sold a total of 22,403 shares worth more than $1,646,312.57. The most recent insider tranaction occured on July, 28th when COO Michael Lee Brooks sold 1,002 shares worth more than $78,156.00. Insiders at Syneos Health own 0.3% of the company.
Learn More about insider trades at Syneos Health. Information on this page was last updated on 7/28/2022.
